Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 417

Results For "ED"

10364 News Found

Eli Lilly to spotlight groundbreaking BTK inhibitor Jaypirca at ASH 2025
R&D | November 25, 2025

Eli Lilly to spotlight groundbreaking BTK inhibitor Jaypirca at ASH 2025

Jaypirca is making waves in the fight against B-cell malignancies


Alzheimer’s testing goes painless, homebound with Neurogen-Tasso partnership
R&D | November 25, 2025

Alzheimer’s testing goes painless, homebound with Neurogen-Tasso partnership

The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating


Abbott to acquire Exact Sciences for $21 billion
News | November 25, 2025

Abbott to acquire Exact Sciences for $21 billion

Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology


GE HealthCare to acquire Intelerad for $2.3 billion, expanding cloud and AI imaging footprint
Healthcare | November 25, 2025

GE HealthCare to acquire Intelerad for $2.3 billion, expanding cloud and AI imaging footprint

The deal accelerates GE HealthCare’s digital transformation, expanding its reach into outpatient care and enterprise imaging—a $2 billion-plus growth market


FDA nod to groundbreaking bladder cancer combo therapy for surgery patients
Drug Approval | November 24, 2025

FDA nod to groundbreaking bladder cancer combo therapy for surgery patients

Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options


Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets
Drug Approval | November 24, 2025

Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets

Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhoea


Lupin receives 7 observations from USFDA for Goa manufacturing facility
Drug Approval | November 24, 2025

Lupin receives 7 observations from USFDA for Goa manufacturing facility

Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe